¶ 炎性衰老生物标志物
炎性衰老 (Inflammaging) 是指随着年龄增长而发展的慢性低度炎症，它会导致与年龄相关的疾病。炎性衰老的生物标志物有助于评估炎症状态并监测抗炎干预措施的有效性。这种现象代表了最显著的衰老标志之一，也是长寿干预的关键靶点。
¶ 概述
炎性衰老的特征是促炎细胞因子和标志物水平升高，并在整个衰老过程中持续存在。这些生物标志物为了解炎症状态和疾病风险提供了深入的见解。炎性衰老的概念最早由 Claudio Franceschi 提出，代表了将衰老理解为一种促炎状态的根本性转变。[1]
炎症反应虽然在年轻时对宿主防御至关重要，但随着年龄的增长会变得失调，导致慢性低度炎症，进而引起组织损伤和功能衰退。[2] 这种与年龄相关的炎症状态不同于急性炎症，其特征是在没有明显感染或损伤的情况下，炎症介质持续升高。
¶ 关键生物标志物
¶ 细胞因子
- 白细胞介素-6 (IL-6)
- 肿瘤坏死因子-α (TNF-α)
- 白细胞介素-1β (IL-1β)
- C反应蛋白 (CRP)
IL-6 被认为是炎性衰老（inflammaging）最可靠的生物标志物之一，其水平随年龄显著增加，并与死亡风险密切相关。[3] TNF-α 在炎症级联反应中起着至关重要的作用，并与多种年龄相关疾病（包括心血管疾病、糖尿病和神经退行性疾病）有关。[4]
¶ 急性期蛋白
- C反应蛋白 (CRP)
- 纤维蛋白原
- 血清淀粉样蛋白 A
- 触珠蛋白
CRP 是最广泛使用的系统性炎症生物标志物，并已被广泛验证为老年人心血管事件和死亡率的预测因子。[5] 纤维蛋白原水平升高与老龄人群中血栓形成和心血管疾病风险增加有关。[6]
¶ 细胞标志物
- 中性粒细胞与淋巴细胞比值
- 单核细胞激活标志物
- T细胞衰老标志物
- 自然杀伤细胞功能
中性粒细胞与淋巴细胞比值（NLR）已成为一种简单但强大的系统性炎症生物标志物，并与不同人群的死亡风险增加有关。[7] T细胞衰老标志物（包括 CD28- T细胞）在衰老过程中升高，并导致免疫功能障碍。[8]
¶ 临床意义
炎性衰老生物标志物与以下因素有关：
- 死亡风险增加
- 年龄相关疾病
- 功能衰退
- 认知障碍
炎症标志物（如 IL-6 和 CRP）水平升高一直与死亡风险增加和年龄相关疾病有关。[9] 慢性炎症已被确定为年龄相关功能衰退和认知障碍的关键驱动因素。[10]
¶ 死亡率与寿命
荟萃分析表明，IL-6 水平升高与老年人全因死亡风险增加 2-3 倍有关。[11] 与单一标志物相比，多种炎症生物标志物的组合对死亡风险具有更强的预测价值。[12]
¶ 年龄相关疾病
炎性衰老（Inflammaging）促成了多种年龄相关疾病的发病机制，包括心血管疾病、2型糖尿病、阿尔茨海默病和癌症。[13] 炎性衰老造成的炎症环境会促进组织损伤，并加速这些疾病的进展。[14]
¶ 功能衰退
慢性炎症与老年人的肌少症、衰弱以及身体功能丧失密切相关。[15] 炎症标志物可预测老龄化人群中残疾的发展和独立生活能力的丧失。[16]
¶ 测量方法
常见方法包括：
- 血液检测
- 多重细胞因子检测组合
- 流式细胞术
- 基因表达分析
¶ 标准化检测
超敏CRP（hs-CRP）检测为低度炎症提供了最可靠的测量方法，并在临床环境中广泛应用。[17] 多重细胞因子检测组合允许同时测量多种炎症标志物，从而提供全面的炎症谱。[18]
¶ 新型方法
单细胞RNA测序揭示了衰老过程中细胞类型特异性的炎症特征，为炎性衰老机制提供了新的见解。[19] 代谢组学分析已经鉴定出可能作为炎性衰老新型生物标志物的炎症代谢物。[20]
¶ 治疗意义
这些生物标志物有助于：
- 评估干预措施的有效性
- 监测治疗反应
- 识别高风险个体
- 指导个性化治疗方案
¶ 干预监测
炎性衰老 (Inflammaging) 生物标志物可作为长寿干预 (Longevity Interventions) 临床试验的关键终点，使研究人员能够评估针对慢性炎症的治疗效果。[21] 干预后炎症标志物的减少与健康结果的改善和疾病风险的降低相关。[22]
¶ 个性化医疗
个体的炎症谱可以指导个性化的治疗方案，高风险个体可能会从更积极的抗炎干预中获益。[23] 生物标志物指导的治疗在改善年龄相关疾病的预后方面已显示出良好的前景。[24]
¶ 参见
¶ 参考文献
Franceschi C, Bonafè M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244-254. https://pubmed.ncbi.nlm.nih.gov/10911963/ ↩︎
López-Otín C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell. 2013;153(6):1194-1217. https://www.cell.com/cell/fulltext/S0092-8674(13)00645-4 ↩︎
Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000;51:245-270. https://pubmed.ncbi.nlm.nih.gov/10774463/ ↩︎
Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-867. https://www.nature.com/articles/nature05485 ↩︎
Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836-843. https://www.nejm.org/doi/full/10.1056/NEJM200003233421202 ↩︎
Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA. 1987;258(9):1183-1186. https://pubmed.ncbi.nlm.nih.gov/3625968/ ↩︎
Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. https://academic.oup.com/jnci/article/106/6/dju124/1012390 ↩︎
Effros RB, Dagarag M, Spaulding C, Man J. The role of CD8+ T-cell replicative senescence in human aging. Immunol Rev. 2005;205:147-157. https://pubmed.ncbi.nlm.nih.gov/15882350/ ↩︎
Franceschi C, Garagnani P, Parini P, et al. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576-590. https://www.nature.com/articles/s41574-018-0059-4 ↩︎
Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15(9):505-522. https://www.nature.com/articles/s41569-018-0064-2 ↩︎
Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol. 2004;39(5):687-699. https://pubmed.ncbi.nlm.nih.gov/15130663/ ↩︎
Varadhan R, Yao W, Matteini A, et al. Simple biologically informed inflammatory index of two serum cytokines predicts 10 year all-cause mortality in older adults. J Gerontol A Biol Sci Med Sci. 2014;69(2):165-173. https://pubmed.ncbi.nlm.nih.gov/23682161/ ↩︎
Chung HY, Cesari M, Anton S, et al. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev. 2009;8(1):18-30. https://pubmed.ncbi.nlm.nih.gov/18692159/ ↩︎
Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317-325. https://www.nature.com/articles/nature10146 ↩︎
Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci. 2002;57(5):M326-M332. https://pubmed.ncbi.nlm.nih.gov/11983728/ ↩︎
Penninx BW, Kritchevsky SB, Newman AB, et al. Inflammatory markers and incident mobility limitation in the elderly. J Am Geriatr Soc. 2004;52(7):1105-1113. https://pubmed.ncbi.nlm.nih.gov/15209645/ ↩︎
Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511. https://www.ahajournals.org/doi/full/10.1161/01.cir.0000052939.59093.45 ↩︎
Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007;13(11):1359-1362. https://www.nature.com/articles/nm1653 ↩︎
Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111-121. https://www.nejm.org/doi/full/10.1056/NEJMoa1701719 ↩︎
Menni C, Kastenmüller G, Petersen AK, et al. Metabolomic markers reveal novel pathways of ageing and early development in human populations. Int J Epidemiol. 2013;42(4):1111-1119. https://pubmed.ncbi.nlm.nih.gov/24038796/ ↩︎
Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554-563. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(19)30094-0/fulltext ↩︎
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131. https://www.nejm.org/doi/full/10.1056/NEJMoa1707914 ↩︎
Belsky DW, Caspi A, Houts R, et al. Quantification of biological aging in young adults. Proc Natl Acad Sci U S A. 2015;112(30):E4104-E4110. https://www.pnas.org/doi/10.1073/pnas.1506264112 ↩︎
Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319-328. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32814-3/fulltext ↩︎